Radiation Treatment Time and Overall Survival in Locally Advanced Non-small Cell Lung Cancer

McMillan, Matthew T.; Ojerholm, Eric; Verma, Vivek; Higgins, Kristin; Singhal, Sunil; Predina, Jarrod D.; Berman, Abigail T.; Grover, Surbhi; Robinson, Clifford G.; Simone, Charles B.

doi:10.1016/j.ijrobp.2017.04.004

Cited by 74 publications

(58 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society, which consists of deidentified information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the U.S. population. [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] The NCDB contains information not included in the Surveillance, Epidemiology, and End Results database, including details regarding use of systemic therapy and the dose of radiotherapy (RT). The data used in the study were derived from the deidentified NCDB NPC file (there were no other subsite files utilized).…”

Section: Ate Ri Als An D Me Tho Dsmentioning

confidence: 99%

Human papillomavirus and nasopharyngeal cancer

2018

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Ate Ri Als An D Me Tho Dsmentioning

confidence: 99%

Human papillomavirus and nasopharyngeal cancer

2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies have shown that patients with Medicaid insurance or no insurance are less likely to receive recommended cancer treatments than patients with private insurance (16)(17)(18). Compared to patients with private insurance, patients with lung cancer with no insurance or public insurance have higher mortality, more treatment delays, and are less likely to receive molecular testing, chemotherapy, or radiation (9,(19)(20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

Disparities in Systemic Treatment Use in Advanced-stage Non–Small Cell Lung Cancer by Source of Health Insurance

Maguire

Morris

Parikh‐Patel

et al. 2019

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Management of advanced-stage non-small cell lung cancer (NSCLC) has changed significantly over the past two decades with the development of numerous systemic treatments, including targeted therapies. However, a high proportion of advanced-stage patients are untreated. The role that health insurance plays in receipt of systemic treatments is unclear.Methods: Using California Cancer Registry data (2012-2014), we developed multivariable Poisson regression models to assess the independent effect of health insurance type on systemic treatment utilization among patients with stage IV NSCLC. Systemic treatment information was manually abstracted from treatment text fields.Results: A total of 17,310 patients were evaluated. Patients with Medicaid/other public insurance were significantly less likely to receive any systemic treatments [risk ratio (RR), 0.78; 95% confidence interval (CI), 0.75-0.82], bevacizumab combinations (RR, 0.57; 95% CI, 0.45-0.71), or tyrosine kinase inhibitors (RR, 0.70; 95% CI, 0.60-0.82) compared with the privately insured. Patients with Medicare or dual Medicare-Medicaid insurance were not significantly different from the privately insured in their likelihood of receiving systemic treatments.Conclusions: Substantial disparities in the use of systemic treatments for stage IV NSCLC exist by source of health insurance in California. Patients with Medicaid/other public insurance were significantly less likely to receive systemic treatments compared with their privately insured counterparts.Impact: Source of health insurance influences care received. Further research is warranted to better understand barriers to treatment that patients with Medicaid face.

show abstract

“…The NCDB is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society, which consists of deidentified information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the US population. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] All pertinent cases are reported regularly from CoC-accredited centers and compiled into a unified data set, which is then validated. The NCDB contains information not captured in the SEER database, including details regarding use of systemic therapy.…”

Section: Methodsmentioning

confidence: 99%

Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes

Verma¹,

Surkar²,

Brooks³

et al. 2018

J Natl Compr Canc Netw

Self Cite

View full text Add to dashboard Cite

Current guidelines recommend chemotherapy (CT) with or without radiotherapy for unresected nonmetastatic gallbladder cancer (GC), with little consensus. However, several small-volume, single-institution studies have documented the efficacy of local therapy for this population. This is the largest study to date evaluating outcomes of chemoradiotherapy (CRT) versus CT alone in unresected nonmetastatic GC. The National Cancer Database was queried for primary GC cases (2004-2013) receiving CT alone or CRT. Patients receiving resection or lack of CT were excluded, as were those with metastatic disease or unknown M classification. Logistic regression analysis ascertained factors associated with CRT delivery. Kaplan-Meier analysis evaluated overall survival (OS) between both cohorts. Cox proportional hazards modeling determined variables associated with OS. In total, 1,199 patients were analyzed (CRT: n=327, 27%; CT: n=872, 73%). Groups were evenly balanced, with no factor on multivariate logistic regression analysis statistically predicting for receipt of a particular paradigm. Median OS in the CRT and CT groups was 12.9 versus 7.8 months, respectively (=.001). On multivariate analysis, OS was associated with age and years of treatment (=.001 each). Notably, receipt of CRT independently predicted for improved OS (=.001). CRT, compared with CT alone, was independently associated with improved survival in unresected nonmetastatic GC. Although causation is not implied, these results support the necessity for prospective CRT evaluation.

show abstract

Radiation Treatment Time and Overall Survival in Locally Advanced Non-small Cell Lung Cancer

Cited by 74 publications

References 29 publications

Human papillomavirus and nasopharyngeal cancer

Human papillomavirus and nasopharyngeal cancer

Disparities in Systemic Treatment Use in Advanced-stage Non–Small Cell Lung Cancer by Source of Health Insurance

Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes

Contact Info

Product

Resources

About